**ISSFAL BOARD CANDIDATE STATEMENT**

**December 2016**

Professor Samar Basu

Samar Basu is a Professor of Biochemistry and Medical Inflammation at the Faculty of Pharmacy, Université d´Auvergne-Clermont, Clermont-Ferrand, France, and also acted as Research Section Head of “Oxidative Stress and Inflammation” at the Faculty of Medicine, Uppsala University, Uppsala, Sweden. He was also a Visiting Scientist at the Harvard Medical School, Boston, USA. He primarily trained in Clinical Chemistry, and obtained his M.Sc. (Reproductive Endocrinology, 1984) and Ph.D. (Reproductive Endocrinology/Obstetrics Gynaecology, 1988) specifically on the role of prostaglandins in pregnancy from the Faculty of Veterinary Medicine, Uppsala under supervision of Prof. Hans Kindahl who is a descendant from Prof. Bengt Samuelsson’s pioneering prostaglandin laboratory at the Karolinska Institute, Stockholm. Soon after that he joined with Prof. Johan Stjernschantz, Glaucoma Research Laboratory at the Pharmacia, Uppsala (currently under Pfizer) as a Scientist for prostaglandin drug discovery against Glaucoma. He had a key role as a Study Director on the studies of pharmacokinetics, metabolism and toxicokinetics, and detection/quantification of Latanoprost (XalatanR) with other prostaglandin analogues by liquid and other chromatography/LC-MS and radioimmunoassay that were later came into the clinical phases I-IV. Discovery of low 15-PGDH and high 13-reductase that regulate prostaglandins in addition to esterases in the mammalian eye (first published in Acta Chem Scand. 46, 108-110, 1992) lead to significant contribution to the novel selection, development and finally registration of XalatanR world-wide in 1996 as a first prostaglandin F2-based drug against Glaucoma. Today XalatanR is a first hand block-buster drug against Glaucoma and usages by millions globally.

After that he joined Uppsala University where he devoted his research on inflammation and oxidative stress in diseases, specifically the role of lipids (prostaglandins, isoprostanes etc.) in inflammation and experimental and clinical cardiovascular diseases in addition to development of eicosanoids assays. In 2010 he was recruited by the Université d´Auvergne-Clermont and Conseil d’Auvergne, Clermont-Ferrand, France as a Chaire d’Excellence Professor to establish a research program on eicosanoids and other inflammatory pathways in breast cancer. His research over 37 years is primarily based on the eicosanoid biosynthesis and metabolism.

His contact with the ISSFAL was from the foundation meeting of ISSFAL in Adelaide, Australia in 1992 in conjunction with the “Third International Congress On Essential Fatty Acids and Eicosanoids” organized by Prof. Andrew Sinclair and Prof. Bob Gibson where he was a speaker with his innovative paper on prostaglandin analogues (that ended to drug well-known XalatanR) for Glaucoma treatment from Pharmacia. He instantly became a member of ISSFAL from the start in 1992. Eicosanoids came to highlight at the ISSFAL meeting in Stockholm in 2014 where he was one of the local organizer and chairman of “Lipid Oxidation” session. In ISSFAL meeting in 2016 in Cape Town, he was a speaker in the “Eicosanoids, Docosanoids and Related Bioactive Lipids” session on “Inflammation and Breast Cancer” and also chairman of “Lipidomics and Metabolomics” session. He is an author of about 250 scientific papers, 29 research papers as Study Director and main author at Pharmacia, and Editor of “Studies of Experimental Models: Oxidative Stress in Applied Basic Research and Clinical Practice” and also served as an Associate Editor of “Journal Of Alzheimer´s Diseases” among others. He has also served as an Expert Committee Member of “Nordic Nutrition Recommendation”, The Nordic Minstry, 2012 and had numerous research collaboration world-wide, including NIH, NCI and Harvard Medical School, USA and EU projects. He acts as an advisor of eicosanoids research in a private company.

He is greatly honored to be nominated to serve the Board of ISSFAL, and with his long pre-clinical and clinical research with lipids/eicosanoids background in academics and industrial academics and being a member from the start he would execute his best to positively contribute for ISSFAL Board if such opportunity is given.

Candidature supported by the Nominations Committee, ISSFAL Board of Directors.